FDA
-
-
-
-
-
-
-
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
-
-
-
-
-
-
-
Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
-
-
-
-
-
-
-
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
-
-
-
-
-
-
-
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
-
-
-
-
-
-
-
Enliven Therapeutics stock surges 28% on Merck-Terns deal
-
-
-
-
-
-
-
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
-
-
-
-
-
-
-
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlie
-
322,948 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

